(CercleFinance.com) – Boiron publishes a turnover of 534 ME for the 2022 financial year, up 17.4% compared to 2021.
At the same time, operating profit was up by 35.5%, at 63 ME, while net profit group share amounted to 44.6 ME, up 56.4% in one year.
In 2023, the Group’s sales growth will potentially be impacted by the decline in sales of COVID tests, by the tension on the supply of raw materials and energy, and by the geopolitical situation in certain regions of the world, estimates Boiron.
‘We continue to put all our energy and determination so that every patient in the world can benefit from homeopathy and our other health solutions, in order to participate in the development of a health system that is more humane, more efficient and more sustainable’, concludes the company.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
